Navigation Links
Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
Date:5/23/2017

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology” in Nature Precision Oncology on May 8th. The peer reviewed publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes the use of Vortex technology for the isolation and characterization of CTCs from 22 patients with advanced prostate cancer. CTCs can provide both genetic and phenotypic information about tumor evolution, potentially from both primary and metastatic sites. In this paper, the utility of the Vortex technology to support the capture and characterization of CTCs from prostate cancer patients was demonstrated.

The Vortex technology isolates and collects CTCs directly from whole blood based on the greater deformability and larger size of the cells. CTCs are collected unbiased by their molecular characteristics and available for a wide range of analysis, providing a window into a patient’s cancer biology. The paper describes the capturing of CTCs from prostate cancer patients with high purity (from 1.74 to 37.59%) and efficiency (from 1.88 to 93.75 CTCs/7.5mL). Interestingly, atypical large circulating cells were identified in 5 age-matched healthy donors (46-77 years old; 1.25-2.5 CTCs/7.5 mL) but not in 5 healthy donors <30 years-old (21-27 years old; 0.00 CTC/7.5 mL). Using a threshold calculated from the 5 age-matched healthy donors (3.37 CTCs/mL), CTCs were identified at levels above the healthy threshold in 80% of the prostate cancer patients. A fraction of the cells collected (11.5%) did not express epithelial prostate markers (CK and/or PSA) and some instead expressed markers of epithelial-mesenchymal transition (EMT), i.e. vimentin and N-cadherin.

"We are excited to see how effective the Vortex technology is for isolating CTCs independent of their epithelial properties, making them available for both genomic and phenotypic analysis,“ said Dr. Dino Di Carlo, Director of the Microfluidic Biotechnology Laboratory at UCLA and Director of the Cancer Nanotechnology Program of the Jonsson Comprehensive Cancer Center. "The work demonstrated in this paper shows what a powerful window into patient cancer biology CTCs can be with the right collection system."

The fully automated VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. The Vortex system utilizes a proprietary microfluidic chip to stably trap and capture CTCs in micro-scale vortices based on their larger size and greater deformability than the white and red blood cells. With excellent CTC recovery, best in class CTC purity, and collected CTCs being viable, and ready for downstream analysis, the VTX-1 offers the best CTC samples available today.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14354838.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
2. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board
5. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
6. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
7. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
8. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
9. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
10. TOMA Biosciences Releases the COMPASS Tumor Profiling System
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... ... Cheyenne is a beautiful and strong Quarter Horse and a huge part of ... , which offers riding lessons and trail riding in Afton, Virginia. According to ... her as her “go to horse.” Thus, you can imagine the devastation when ...
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., ... announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. ... facility demonstrates the company's continuous commitment to quality research and service offerings. ...
(Date:9/24/2019)... , ... September 24, 2019 , ... Drug resistance has ... the World Health Organization, with MRSA becoming one of the most serious concerns. Hong ... 1,218 reported cases of community-associated MRSA (CA-MRSA), or a seven-fold of the figure in ...
(Date:9/24/2019)... S.D. (PRWEB) , ... September 24, 2019 , ... In ... funding for research led by faculty at South Dakota School of Mines & ... the tiny microbes that attach to surfaces to form a slimy and yet strong ...
Breaking Biology Technology:
(Date:9/30/2019)... ... September 30, 2019 , ... USDM Life Sciences ... life science organizations to accelerate innovation and maximize productivity, announces that David Blewitt ... What: Just 30 days to 21 CFR Part 11 compliance with Box, When: ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... organization focused on molecular manufacturing and other transformative technologies, announced the 2018 ... College graduate or undergraduate student whose work is considered most notable in ...
(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech , an exclusive ... announces its inaugural South CEO conference to be held on October ... by Tulane University, this invitation-only meeting convenes biopharma executives to discuss pressing issues ...
Breaking Biology News(10 mins):